Skip to business profile
Loading public business profile Reading the canonical Directory record.
Loading profile
Public Directory
Public business profile

Business profile

Loading canonical business information.

— — —
Registry verification — business evidence
Directory Score — Public record strength, not a rating
Data confidence — public data confidence
Freshness — record lifecycle
ASG Gateway —
Business profile

About

For people, developers and AI

AI-readable discovery

Public information

Read the structured business information and inspect the published discovery documents.

Machine-readable documents do not by themselves establish a live AI agent, checkout or business ownership.

Talk to the business

Request a quote

Loading quote availability…

Public business listing Owner sign-in Suggest a correction
Report this listing

Tell us what needs reviewing. Removal requests are reviewed before any change is made.

Request removal
Profile information

Publication, owner access and business registry verification are separate. Verification badges describe the checks completed; public references identify this listing.

Structured public business summary

Oxford BioDynamics PLC

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments. The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment. OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health. Oxford BioDynamics has participated in more than 40 partnerships with pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases. OBD is headquartered in Oxford, UK and is listed on the London Stock Exchange’s AIM market. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA and a reference laboratory in Penang, Malaysia.

Oxford,, United Kingdom

Official website

Machine-readable JSON profile

Business nature

Primary business nature
Not provided
Customer market
Not provided

Operating hours

Hours not provided.

Categories

  • Healthcare & Medical (primary)

Service areas

  • Oxford,, United Kingdom

Public contacts

Declared AI capabilities

  • Online booking — Detected from public website navigation or discovery metadata.
  • Online support — Detected from public website navigation or discovery metadata.

Directory status

Registry verification: Registry Verified

Directory score: 90

Public source evidence